Intec Pharma Ltd.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

David Kirmayer

Elena Kluev

Nadav Navon

Giora Carni

Eytan Moor

Julia Shvetz

Eva Abramov

Zeev Weiss

Michael M Friedman

Doron Steinberg

Rami Mosheiff

Jacob Rachmilewitz

Suher Masri

Amal Khoury

Provided herein injectable implant compositions useful for acceleration of bone fracture healing, treatment of dental or oral pathologies, and controlled drug delivery.

Injectable implants

The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.

Accordion pill comprising levodopa for an improved treatment of Parkinson's Disease symptoms

A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.

Zaleplon gastroretentive drug delivery system

The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.

Accordion pill comprising levodopa for an improved treatment of Parkinson's disease symptoms

A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.

Carbidopa/levodopa gastroretentive drug delivery

Carbidopa/Levodopa gastroretentive drug delivery

Growing community of inventors

Maale Adumim, Israel

David Kirmayer